{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274318","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.028570+00:00","generated_at":"2026-05-16T22:47:20.873770+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Perspective Therapeutics reports Q3 2025 net loss of $26.0M; cash $174M into late 2026","bullets":["Net loss $26.0M ($0.35/sh) vs $15.1M ($0.21) in Q3 2024; R&D spend $20.3M up 69% YoY.","Cash $174M as of Sep 30, 2025, down from $227M at Dec 31, 2024; runway into late 2026.","Clinical: VMT-α-NET cohort 3 opened June 2025, 8 patients enrolled; favorable safety in 55 patients.","VMT01 melanoma: 5 patients dosed at 3.0 mCi (monotherapy or +nivolumab) as of Oct 31, 2025.","PSV359 FAP-α therapy: 3 patients treated as of Oct 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274318","json":"https://secwatch.observer/filing/0001193125-25-274318.json","markdown":"https://secwatch.observer/filing/0001193125-25-274318.md","text":"https://secwatch.observer/filing/0001193125-25-274318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/0001193125-25-274318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/catx-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:47:20.873770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}